Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 28, 2023

Cancer Vaccine OSE2101 vs Chemotherapy in HLA-A2–Positive Patients With Advanced NSCLC Resistant to Immunotherapy

Annals of Oncology


Additional Info

Annals of Oncology
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
Ann. Oncol 2023 Aug 01;[EPub Ahead of Print], B Besse, E Felip, RG Campelo, M Cobo, C Mascaux, A Madroszyk, F Cappuzzo, W Hilgers, G Romano, F Denis, S Viteri, D Debieuvre, D Galetta, E Baldini, M Razaq, G Robinet, M Maio, A Delmonte, B Roch, P Masson, W Schuette, A Zer, J Remon, D Costantini, B Vasseur, R Dziadziuszko, G Giaccone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading